Eisai - Crunchbase Company Profile & Funding

Q: Where is Eisai's headquarters?

Eisai is located in Tokyo, Tokyo, Japan.

Overview

Eisai

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Eisai

CB Rank

114336

Eisai is a pharmaceutical company that researches and delivers medicines for patients.

Acquired by

Royalty Pharma

Founded

obfuscation

Public

Tokyo, Tokyo, Japan

10001+

www.eisai.co.jp/index.html

Biotechnology

Health Care

Pharmaceutical

Key People

Yuji Matsue: Chairman & CEO
Wil Foster: Director Regulatory Affairs

Details

Legal Name

Eisai Co., Ltd.

Also Known As

エーザイ

Operating Status

Active

Number of Exits

obfuscation

Stock Symbol

TYO:4523

Company Type

For Profit

Founders

Haruo Naito, Yasushi Okada

About the Company

Eisai is a human healthcare company that provides products and services to its patients and their families under any healthcare system. They specialize in an integrated pharmaceutical business that operates in business groups and focuses on oncology and neurology, dementia-related diseases, and neurodegenerative diseases.

Phone Number

+81 3 3817 3700

Predictions & Insights

Growth Insight

See this Growth Insight

Eisai is

Lorem

to be growing

Top Contributing Factors

Financial Growth

Products & Services

Leqembi® (Lecanemab)

A treatment for early Alzheimer's disease that targets amyloid pathology to slow disease progression in adults with mild cognitive impairment or mild dementia.

Lenvima® (Lenvatinib)

An oral tyrosine kinase inhibitor used to treat various cancers including thyroid, liver, and kidney cancers by inhibiting tumor growth and angiogenesis.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Investments

Investment Breakdown

Diversity Investments

Number of Investments

Number of Exits

obfuscation

Number of Acquisitions

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Beren Therapeutics	—	Venture Round - Beren Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Beren Therapeutics	—	Venture Round - Beren Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Beren Therapeutics	—	Venture Round - Beren Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Beren Therapeutics	—	Venture Round - Beren Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Beren Therapeutics	—	Venture Round - Beren Therapeutics	obfuscated obfuscation

Investment Breakdown

Number of Investments

Number of Exits

obfuscation

Number of Acquisitions

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Beren Therapeutics	—	Venture Round - Beren Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Beren Therapeutics	—	Venture Round - Beren Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Beren Therapeutics	—	Venture Round - Beren Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Beren Therapeutics	—	Venture Round - Beren Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Beren Therapeutics	—	Venture Round - Beren Therapeutics	obfuscated obfuscation

Diversity Investments

Number of Diversity Investments

Announced Date	Organization Name	Diversity Spotlight	Funding Round	Money Raised
obfuscated obfuscation	Casma Therapeutics	Women Founded	Series C - Casma Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Darmiyan	Women Founded, Women Led	Seed Round - Darmiyan	obfuscated obfuscation